Search details
1.
Neutrophils are mediators of metastatic prostate cancer progression in bone.
Cancer Immunol Immunother
; 69(6): 1113-1130, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32114681
2.
Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy.
Int J Mol Sci
; 20(11)2019 Jun 08.
Article
in English
| MEDLINE | ID: mdl-31181800
3.
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
Cancer Control
; 22(1): 109-20, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25504285
4.
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.
Nat Commun
; 15(1): 2458, 2024 Mar 19.
Article
in English
| MEDLINE | ID: mdl-38503736
5.
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.
Sci Adv
; 9(18): eadf0108, 2023 05 03.
Article
in English
| MEDLINE | ID: mdl-37134157
6.
Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.
Cancers (Basel)
; 13(4)2021 Feb 08.
Article
in English
| MEDLINE | ID: mdl-33567529
7.
Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.
Nat Commun
; 12(1): 723, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33526787
8.
Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis.
Neoplasia
; 22(10): 511-521, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32896761
9.
CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms.
BioDrugs
; 33(6): 647-659, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-31552606
10.
Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.
Oncogene
; 38(44): 6959-6969, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31409900
Results
1 -
10
de 10
1
Next >
>>